Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-3504 in Healthy Subjects and Ulcerative Colitis
NCT03103412Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TD-3504 in ulcerative colitis (UC), sponsored by Theravance Biopharma, Inc. Primary endpoint: Safety & tolerability of TD-3504 by assessing the number, severity, and type of adverse events. Started May 2017; status: completed.
02
Drugs
TD-3504
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03103412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103412.